Hereditary Cancer DNA Testing in India: BRCA, Lynch Syndrome & What to Expect
According to Indian cancer registry data, India records over 1.4 million new cancer cases annually - and a meaningful proportion are hereditary, caused by inherited gene variants passed from parent to child across generations. Awareness of hereditary cancer genetic testing is growing in India but remains limited, and many families do not yet know that their cancer risk could potentially be identified - and acted upon - years before diagnosis.
If you have a family history of breast cancer, ovarian cancer, colorectal cancer, or other cancers - especially diagnosed at young ages or in multiple relatives - a hereditary cancer DNA test may be one of the most important medical decisions you make. Identifying a pathogenic variant allows your entire family to be offered testing, and those who test positive can begin enhanced surveillance and risk-reduction interventions before cancer ever develops.
Key Indian context: Breast cancer is now the most common cancer in Indian women, accounting for approximately 27% of all female cancers according to Indian cancer registry data. As reported in medical literature, an estimated 5-10% of all breast cancers are hereditary - driven primarily by BRCA1 and BRCA2 gene variants. India has a distinct spectrum of BRCA variants compared to Western populations, meaning Western-focused tests may miss Indian-specific pathogenic mutations.
What Is Hereditary Cancer?
Most cancers arise from random mutations that accumulate in cells over a lifetime - these are called sporadic cancers and are not inherited. But according to published research, approximately 5-10% of all cancers are hereditary - caused by variants in specific genes that are present in every cell of the body from birth and can be passed from parent to child.
A person who inherits a pathogenic variant in a cancer predisposition gene does not inevitably develop cancer. Rather, they start life with one "hit" already present in their cells. When a second mutation occurs - through normal ageing or environmental exposure - the cell may lose tumour-suppressor function and begin the path to malignancy. This is the two-hit model of cancer predisposition.
Crucially, these variants can be identified through genetic testing before cancer develops - allowing preventive action rather than reactive treatment.
The Most Important Hereditary Cancer Genes for Indians
BRCA1 and BRCA2: Hereditary Breast and Ovarian Cancer
BRCA1 and BRCA2 are tumour suppressor genes involved in DNA repair. According to published research, pathogenic variants in these genes substantially increase lifetime cancer risk:
- BRCA1 variant carriers: approximately 50-72% lifetime breast cancer risk; approximately 44% lifetime ovarian cancer risk
- BRCA2 variant carriers: approximately 45-69% lifetime breast cancer risk; approximately 17-23% lifetime ovarian cancer risk; elevated prostate cancer risk in men
BRCA variants are found in Indian populations at measurable frequencies. Importantly, Indian BRCA variants are distinct from the Ashkenazi Jewish founder mutations (185delAG, 5382insC, 6174delT) that Western tests prioritise. A comprehensive South Asian BRCA analysis must cover the full coding regions of both genes to capture India-specific pathogenic variants. Partial panels designed for Western populations will miss a significant proportion of pathogenic variants in Indian patients.
Lynch Syndrome: Hereditary Colorectal and Endometrial Cancer
Lynch syndrome is caused by pathogenic variants in the mismatch repair (MMR) genes: MLH1, MSH2, MSH6, and PMS2. According to published research, it is the most common hereditary colorectal cancer syndrome, accounting for approximately 3-5% of all colorectal cancers. People with Lynch syndrome have significantly elevated risks of:
- Colorectal cancer (approximately 40-80% lifetime risk, according to medical literature)
- Endometrial cancer (approximately 25-60% lifetime risk in women)
- Ovarian, gastric, pancreatic, urinary tract, and other cancers
Awareness of Lynch syndrome is growing in India, though diagnosis rates remain low. As reported in medical literature, most Lynch syndrome families are identified only after one member develops colorectal cancer - often because genetic testing was not yet widely available or offered. Proactive genetic testing allows at-risk family members to enter enhanced surveillance with colonoscopy every 1-2 years, catching polyps before they become cancers.
Other Hereditary Cancer Genes Screened by Helixline
- PALB2 - Moderate to high breast cancer risk (33 - 58% lifetime), often called the "third BRCA gene"
- ATM - Elevated breast cancer risk; associated with ataxia-telangiectasia when two copies are affected
- CHEK2 - Moderate breast cancer risk; common in certain European populations, also found in Indians
- APC - Familial adenomatous polyposis (FAP), causing hundreds to thousands of colorectal polyps and near-certain colorectal cancer without prophylactic colectomy
- CDH1 - Hereditary diffuse gastric cancer; gastric cancer is relatively common in certain South Indian communities
- TP53 - Li-Fraumeni syndrome, associated with early-onset breast cancer, sarcomas, brain tumours, and other cancers
- PTEN - Cowden syndrome, associated with breast, thyroid, and endometrial cancers
- STK11 - Peutz-Jeghers syndrome, associated with gastrointestinal polyps and elevated cancer risk in multiple sites
Who Should Consider Hereditary Cancer DNA Testing in India
Hereditary cancer testing is particularly recommended for:
- Any woman with breast cancer diagnosed before age 45 - early-onset breast cancer has a significantly higher probability of hereditary causation
- Anyone with bilateral breast cancer - cancer in both breasts strongly suggests hereditary predisposition
- Anyone with breast cancer AND ovarian cancer in the same person or family
- Male breast cancer patients - rare but often hereditary; BRCA2 is the most common cause
- Anyone with triple-negative breast cancer under age 60 - TNBC has a higher proportion of BRCA1-associated cases
- Families with multiple colorectal cancer cases, especially at young ages
- Anyone with a known pathogenic variant in the family - first-degree relatives of a known carrier should all be offered testing
- Ashkenazi Jewish ancestry - the three founder mutations are common enough that proactive BRCA testing is recommended even without family history
- Anyone with a personal or family history of ovarian cancer - most ovarian cancer is difficult to detect early; identifying hereditary risk allows prophylactic salpingo-oophorectomy
What Happens After a Positive Test
A positive hereditary cancer genetic test does not mean you will develop cancer. It means your risk is significantly elevated compared to the general population - and that elevated risk can be managed. Standard management options include:
- Enhanced surveillance: Annual MRI breast screening from age 25 - 30 for BRCA1/2 carriers (more sensitive than mammography for high-risk women); annual colonoscopy from age 25 for Lynch syndrome; regular ovarian surveillance
- Risk-reducing medications: Chemoprevention with tamoxifen or aromatase inhibitors for BRCA-positive women; aspirin for Lynch syndrome
- Risk-reducing surgery: Prophylactic mastectomy reduces breast cancer risk by >90% in BRCA carriers; bilateral salpingo-oophorectomy reduces ovarian cancer risk by >80% and also reduces breast cancer risk in premenopausal BRCA1 carriers
- Family cascade testing: First-degree relatives (parents, siblings, children) of a pathogenic variant carrier should be offered testing so they can also know their status and make informed decisions
Important: Helixline's cancer predisposition screening covers well-characterised pathogenic variants using SNP genotyping, but it is not a substitute for clinical-grade full gene sequencing (such as that performed at certified cancer genetics laboratories). Consumer DNA tests like Helixline screen for known, well-characterised variants - they do not sequence the entire gene and may not detect rare or novel mutations. If you have a strong family history of cancer, consult an oncologist or genetic counsellor about comprehensive clinical testing.
The Role of Genetic Counselling
If your results indicate a cancer predisposition variant, the single most important next step is to speak with a board-certified genetic counsellor before making any medical decisions. A genetic counsellor can help you understand what the result means in the context of your personal and family medical history, discuss the limitations of consumer-grade testing, coordinate confirmatory clinical-grade testing if needed, and guide you through options for surveillance, risk reduction, and family cascade testing. Many hospitals in India now have clinical genetics departments, and teleconsultation services are increasingly available. Do not make surgical or treatment decisions based solely on a consumer DNA test result.
Understanding Variants of Uncertain Significance (VUS)
Not every genetic variant found in a cancer predisposition gene is clearly harmful or clearly harmless. Some results may show a Variant of Uncertain Significance (VUS) - meaning current scientific evidence is not sufficient to classify the variant as either pathogenic or benign. A VUS should not be treated as a positive finding, and medical decisions should not be based on VUS results. Over time, as more research data becomes available, a VUS may be reclassified. Your genetic counsellor can explain what a VUS means for your individual situation and whether any follow-up is appropriate.
Emotional Preparation for Cancer Predisposition Results
Learning about your hereditary cancer risk can be emotionally challenging, even when the information is ultimately empowering. It is entirely reasonable to feel anxious, overwhelmed, or uncertain after receiving results - particularly if a predisposition variant is identified. Before reviewing your results, consider arranging support: let a trusted family member or friend know you are awaiting results, and have the contact details of a genetic counsellor or mental health professional available. Remember that a predisposition result is not a diagnosis - it is information that enables you to take proactive steps.
Know Your Hereditary Cancer Risk
Helixline's Decode kit includes comprehensive cancer predisposition gene screening alongside ancestry analysis and carrier testing. Now at ₹12,999 (MRP ₹20,000) - no clinic visit required. Results in 6-8 weeks. Your data is encrypted and never shared without your explicit consent. Learn more about how we protect your privacy.
Order Decode - ₹12,999Frequently Asked Questions
Should Indians get hereditary cancer genetic testing?
For individuals with relevant family history, hereditary cancer testing can be a valuable step. In practical terms, the National Comprehensive Cancer Network (NCCN) guidelines recommend genetic testing for anyone who meets specific family history criteria - and many Indian families do without realising it. In India, access to genetic testing has expanded significantly in recent years through at-home collection kits, reducing the need for specialised clinic visits. If a pathogenic variant is found, the result can benefit your entire family through cascade testing of first-degree relatives.
What are the most common hereditary cancers in India?
Beyond the five major syndromes (HBOC, Lynch, FAP, hereditary diffuse gastric cancer, and Li-Fraumeni), India also sees notable rates of hereditary retinoblastoma (RB1 gene) in children and hereditary thyroid cancer syndromes. The relative frequency of each syndrome varies by region and community - for example, according to published research, certain founder mutations in BRCA genes have been documented in specific South Indian and Parsi communities. Your family's geographic origin and community background can help a genetic counsellor assess which syndromes are most relevant to investigate.
Are there India-specific BRCA variants not covered by Western tests?
Yes, and this is one of the most important reasons to choose a test designed for South Asian populations. As reported in medical literature, researchers have documented India-specific BRCA founder mutations - such as BRCA1 185delAG in certain Indian Jewish communities and distinct BRCA2 variants in Maharashtrian and South Indian populations - that do not appear on standard Western screening panels. Consumer SNP-based tests like Helixline screen for well-characterised pathogenic variants relevant to Indian populations, but for families with very strong cancer histories, confirmatory full-gene sequencing at a clinical laboratory is recommended.